Will the era of domestic biosimilar successes open?

As the first biosimilar, the Sandoz’s ‘Zarxio (generic name: filgrastim)’, has recently acquired sale approvals in the U.S., biosimilars developed by domestic companies have attracted attention of the industry.

As a domestic biosimilar entered the U.S. market, the largest pharmaceutical market, expectation has increased for domestic biosimilars to expand to the market.

After Celltrion unveile...